Intellia Therapeutics (NTLA) has provided an update.
Intellia Therapeutics has appointed Michael P. Dube as the new principal accounting officer. With a solid background in finance and accounting, Dube brings experience from his previous role as Global Corporate Controller at Abiomed, Inc. and a decade at Deloitte & Touche LLP. His expertise as a certified public accountant reinforces Intellia’s financial leadership team as they continue to innovate in the biotechnology sector.
For a thorough assessment of NTLA stock, go to TipRanks’ Stock Analysis page.
